Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies - Poll - MDSpire

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

  • By

  • Jiazhong Wang

  • Gang Cao

  • Yang Liu

  • Hao Qiao

  • Qiao He

  • Bo Zheng

  • June 22, 2026

  • 0 min

Share

Original Source(s)

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

  • by Jiazhong Wang, Gang Cao, Yang Liu, Hao Qiao, Qiao He, Bo Zheng

  • June 22, 2026

Related Content

Editorial: Precision oncology: integrating molecular mechanisms, organoid models, and omics technologies for personalized cancer care

Antibody-drug conjugates in colorectal cancer: current landscape and future perspectives from clinical trials

Neuro-immune interactions in cancer: mechanisms and therapeutic prospects